THX Pharma
ALTHX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €0 | €35 | €2,213 | €75 |
| % Growth | -100% | -98.4% | 2,864.1% | – |
| Cost of Goods Sold | €48 | €684 | €1,249 | €2,668 |
| Gross Profit | -€48 | -€649 | €964 | -€2,593 |
| % Margin | – | -1,851.7% | 43.6% | -3,472.8% |
| R&D Expenses | €0 | €1,337 | €0 | €2,519 |
| G&A Expenses | €0 | €509 | €1,073 | €983 |
| SG&A Expenses | €1,920 | €515 | €1,118 | €1,032 |
| Sales & Mktg Exp. | €0 | €6 | €44 | €48 |
| Other Operating Expenses | -€817 | -€1,300 | €72 | -€2,408 |
| Operating Expenses | €1,103 | €551 | €1,190 | €1,142 |
| Operating Income | -€1,151 | -€2,371 | -€226 | -€3,777 |
| % Margin | – | -6,766.4% | -10.2% | -5,058.4% |
| Other Income/Exp. Net | €38 | €28 | €36 | €10 |
| Pre-Tax Income | -€1,113 | -€2,343 | -€190 | -€3,768 |
| Tax Expense | -€41 | -€477 | -€291 | -€586 |
| Net Income | -€1,072 | -€933 | €101 | -€3,182 |
| % Margin | – | -2,662.4% | 4.6% | -4,261.1% |
| EPS | -0.13 | -0.11 | 0.013 | -0.41 |
| % Growth | -18.2% | -946.2% | 103.2% | – |
| EPS Diluted | -0.13 | -0.11 | 0.013 | -0.41 |
| Weighted Avg Shares Out | 8,537 | 8,537 | 7,759 | 7,687 |
| Weighted Avg Shares Out Dil | 8,537 | 8,537 | 7,759 | 7,687 |
| Supplemental Information | – | – | – | – |
| Interest Income | €1 | €0 | €0 | €0 |
| Interest Expense | €0 | €120 | €33 | €39 |
| Depreciation & Amortization | €48 | €24 | €47 | €88 |
| EBITDA | -€1,063 | -€1,176 | -€178 | -€3,641 |
| % Margin | – | -3,355.8% | -8.1% | -4,875.7% |